Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes mellitus treatment Gastrointestinal symptoms result from slowed gastric emptying and altered gut motility caused by GLP-1 receptor activation Symptoms are dose-dependent and most commonly occur during initial weeks or following dose escalation Management includes dietary modifications (increased soluble fibre, smaller meals), adequate hydration, and avoiding trigger foods Seek medical advice for persistent diarrhoea beyond 7 days, dehydration signs, blood in stools, or severe abdominal pain Most patients experience symptom improvement over time as physiological adaptation occurs with continued treatment Table of Contents Understanding Loose Stools as a Side Effect of Mounjaro Mounjaro (tirzepatide) is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus
Questionnaires were administered to measure appetite, food cravings, disinhibition, hunger, dietary restraint, susceptibility to food environment and impulsivity
Data availability All data used for the statistical analysis are available in the Source data, along with the GraphPad Prism-derived report on the statistical analysis
10.1002/hipo.20665 Hippocampus
Vitamin C helps regenerate glutathione, extending its antioxidant activity and supporting overall wellness throughout the day
